61
Participants
Start Date
February 15, 2017
Primary Completion Date
July 15, 2019
Study Completion Date
August 28, 2020
Immune-attractant
The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
Durvalumab
Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
Biopsy
After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present \>10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
Institut Paoli Calmettes, Marseille
Centre George François Leclerc, Dijon
Institut Claudius Regaud, Toulouse
Institut Bergonié, Bordeaux
CHU Bretonneau - Centre Henry Kaplan, Tours
Institut Daniel Hollard Groupe Hôspitalier, Grenoble
Centre Hospitalier de Cahors, Cahors
Centre Hôspitalier de Cholet, Cholet
Institut Jean Godinot, Reims
Centre Hospitalier Bretagne Sud, Lorient
Centre Oscar Lambret, Lille
Centre Hospitalier cote Basque, Bayonne
Centre Hospitalier Perpignan, Perpignan
Centre Paul Strauss, Strasbourg
Centre Léon Bérard, Lyon
Institut Curie Site Paris, Paris
Hôpital Saint Louis APHP, Paris
CHU Limoges, Limoges
Institut Curie Hôpital René Huguenin, Saint-Cloud
Gustave Roussy, Villejuif
Centre François Baclesse, Caen
ICO Badalona, Badalona
Hospital Clinic Barcelona, Barcelona
HU Vall Hebron, Barcelona
HU Arnau de Vilanova, Lleida
CIO Clara Campal, Madrid
HU Ramon y Cajal, Madrid
Hospital Clínico Universitario de Valencia, Valencia
Sahlgrenska University Hospital, Gothenburg
Collaborators (1)
Breast International Group
OTHER
UNICANCER
OTHER